MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
About ATH434-202 Phase 2 Clinical Trial The ATH434-202 Phase 2 clinical trial is an open label study, entitled "A Biomarker Study of ATH434 in Participants with MSA." The Biomarker trial enrolled 10 ...
- 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale - - 29% of Participants had Stable or Improved Neurological Symptoms - - Objective Biomarkers Demonstrated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results